➤ Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and
will account for 13,920 deaths.
➤ Opportunities for extended survival and even durable disease control
in the metastatic setting have recently appeared as novel classes of
therapeutics, reshaping the trajectory of this cancer.
➤ This rapid evolution has paved the way for this first set of
comprehensive guidelines for treating metastatic clear cell renal cell
carcinoma (ccRCC).
Recommendation Grading
Type Benefit/harm
Evidence
Quality
Strength of
Recommendation
EB Evidence-based B Benefits
outweigh
harms
H High Strong
CB/
FC
Consensus-
based/Formal
Consensus
H Harms
outweigh
benefits
M Moderate Moderate
IC Informal
consensus
B/H Relative
balance of
benefits
and harms
L Low Weak
N No
recommendation
U Benefits/
harms
ratio
uncertain
Ins Insufficient
Key Points
